Regarding adverse events, Kabel et al16 demonstrated that 70%,100%, and 23.3% of patients in the bleomycin group reported hyperpigmentation, pain, and ulceration, respectively, while 66.7%, 73.3%,and 60% of patients in the 5-FU group experienced hyperpigmentation, ulceration, and pain, respectively. There was no statistical difference for hyperpigmentation between two groups (P = .747). However,pain was more significantly observed in the bleomycin group than the 5-FU group (P = .000), while ulceration rate was statistically increased in the 5-FU group compared to the bleomycin group (P = .001).